John Jordan - Viridian Therapeutics Vice Communications
| 0K1R Stock | 21.82 0.07 0.32% |
Executive
John Jordan is Vice Communications of Viridian Therapeutics
| Address | 221 Crescent Street, Waltham, MA, United States, 02453 |
| Phone | 617 272 4600 |
| Web | https://www.viridiantherapeutics.com |
Viridian Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3215) % which means that it has lost $0.3215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5188) %, meaning that it generated substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Viridian Therapeutics' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 2.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Katherine LLB | Mulberry Group PLC | N/A | |
| Stefan Jost | Uniper SE | N/A | |
| Fabienne Twelemann | Uniper SE | N/A | |
| Nicola McLean | Heavitree Brewery | N/A | |
| SirpaHelena LLM | Uniper SE | 65 | |
| Niek Hollander | Uniper SE | N/A | |
| Carsten Poppinga | Uniper SE | N/A | |
| FCA FCA | Mulberry Group PLC | 75 | |
| Risto MSc | Uniper SE | 56 | |
| Andrew Winton | World Chess PLC | N/A | |
| Nicolo Prien | Uniper SE | 58 | |
| Tina Bradshaw | Uniper SE | N/A | |
| Graham Crocker | Heavitree Brewery | 66 | |
| Ulf Klostermann | Uniper SE | N/A | |
| Christopher Delbrck | Uniper SE | 58 | |
| Richard ACA | London Security Plc | 61 | |
| David Brown | SURETRACK MON | N/A | |
| Sascha Fehlemann | Uniper SE | 46 | |
| Ekaterina Savelyev | World Chess PLC | N/A | |
| Klaus Schaeffer | Uniper SE | 57 | |
| Andrea Baldo | Mulberry Group PLC | 52 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 |
Viridian Therapeutics Leadership Team
Elected by the shareholders, the Viridian Therapeutics' board of directors comprises two types of representatives: Viridian Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viridian. The board's role is to monitor Viridian Therapeutics' management team and ensure that shareholders' interests are well served. Viridian Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viridian Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Seth Harmon, Principal Accounting | ||
| Anthony Casicano, Chief Officer | ||
| Melissa Manno, Chief Officer | ||
| John Jordan, Vice Communications | ||
| Marvin Caruthers, CoFounder Member | ||
| Anthony Casciano, Chief Officer | ||
| MBA JD, President CEO | ||
| Jennifer JD, Chief Officer | ||
| Eric Olson, CoFounder Board | ||
| Vahe Bedian, CoFounder Advisor |
Viridian Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viridian Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (970.70) % | ||||
| Current Valuation | 1.17 B | ||||
| Shares Outstanding | 30.84 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Price To Sales | 11.50 X | ||||
| Revenue | 314 K | ||||
| Gross Profit | (99.12 M) | ||||
| EBITDA | (234.56 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.